Влияние комбинированной терапии индакатеролом и гликопиррония бромидом на состояние респираторной и сердечно-сосудистой систем у пациентов с хронической обструктивной болезнью легких

Респираторная и сердечнососудистая системы тесно взаимосвязаны, при этом в случае хронической обструктивной болезни легких (ХОБЛ) на их статус может оказать влияние терапия бронходилататорами. На примере 2 клинических наблюдений рассматривается возможность перехода от монотерапии индакатеролом к комбинированной терапии индакатеролом и гликопиррония бромидом с анализом динамики изменений соответствующих респираторных и кардиоваскулярных показателей у пациентов с ХОБЛ тяжелой степени. Продемонстрирована тенденция к уменьшению бронхообструкции, улучшению субъективных ощущений, сократительной способности левого и правого желудочков и вариабельности ритма сердца.

1. Global Initiative for Chronic Obstructive Lung Disease (2013) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. www.goldcopd.com

2. Beeh K.M., Beier J. Indacaterol: a new once daily longacting beta2adrenoceptor agonist. Core Evidence. 2009; 4: 37–41.

3. Feldman G., Siler T, Prasad N. et al. Efficacy and safety of indacaterol 150 microg oncedaily in COPD: a doubleblind, randomised, 12week study. BMC Pulm. Med. 2010; 10: 11.

4. Chapman K.R., Rennard S.I., Dogra A. et al. Longterm safety and efficacy of indacaterol, a longacting β2agonist, in subjects with COPD: a randomized, placebocontrolled study. Chest. 2011; 140 (1): 68–75.

5. Dahl R., Chung K.F., Buhl R. et al. Efficacy of a new once daily longacting inhaled β2agonist indacaterol versus twicedaily formoterol in COPD. Thorax. 2010; 65: 473–479.

6. Buhl R., Banerji D. Profile of glycopyrronium for once daily treatment of moderatetosevere COPD. Int. J. COPD. 2012; 7: 729–741.

7. Ulrik C.S. Oncedaily glycopyrronium bromide, a longacting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int. J. COPD. 2012; 7: 673–678.

8. Barnes P.J. Anticholinergic Therapy in Obstructive Airway Disease. Ed. by N.Gross. London; 1993: 88–104.

9. Brown J.H., Taylor P. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. Ed. by J.G. Hardman et al. New York; 1996: 141.

10. Lange P., Mogelvang R., Marott J.L. et al. Cardiovascular morbidity in COPD: a study of the general population. COPD. 2010; 7: 5–10.

11. Konecny T., Park J.Y., Somers K.R. et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am. J. Cardiol. 2014; 15: 114 (2): 272–277.

12. Zulkarneev R., Zagidullin N., Abdrahmanova G. et al. Ivabradine prevents heart rate acceleration in patients with chronic obstructive pulmonary disease and coronary heart disease after salbutamol inhalation. Pharmaceuticals. 2012; 5 (4): 398–404.

13. Hanrahan J.P., Grogan D.R., Baumgartner R.A. et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled longacting beta2agonists arfor moterol and salmeterol. Medicine (Baltimore). 2008; 87 (6): 319–328.

14. Karvandi M., Piranfar M.A., Ghaffaripour M. et al. An alternative method for perioperative estimation of pulmonary artery systolic pressure by echocardiography. Shiraz E*Med. J. 2007; 8: 4:174–182.

15. Curkendall S.M., DeLuise C., Jones J.K. et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann. Epidemiol. 2006; 16: 63–70.

16. Schneider C., Bothner U., Jick S.S., Meier C.R. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur. J. Epidemiol. 2010; 25: 253–260.

17. Roque A.L., Valenti V.E., Massetti T. et al. Chronic obstructive pulmonary disease and heart rate variability: a literature update. Int. Arch. Med. 2014; 3 (7): 43.

18. Forfia P.R., Fisher M.R., Mathai S.C. et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2006; 174 (9): 1034–1041.

19. Worth H., Fan Chung K., Felser K. et al. Cardio and cere brovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir. Med. 2011; 105: 571–579.

20. Bateman E., Ferguson G.T., Barnes N. et al. Dual bron chodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42: 1484–1494.

21. Mahler D., Decramer M., D’Urzo A. et al. Dual bronchodilation with QVA149 reduces patientreported dyspnoea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43: 1599–1609.

22. Wedzicha J., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopy rronium and tiotropium (SPARK): a randomised, double blind, parallelgroup study. The Lancet. Lancet Respir. Med. 2013; 1 (3): 199–209.

23. Zhong N., Wang C., Zhou W. LANTERN: a randomized study of QVa149 versus salmeterol / fluticasone combination in patients with COPD. Int. J. COPD. 2015; 10: 1015–1026.